BOSULIF vs IMKELDI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated June 30, 2026·How we rate

Possible drug interaction. BOSULIF and IMKELDI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BOSULIF	IMKELDI
Rating	New	New
Pharmacy pays	—	~$25.80 /30
Type	RX	RX
Active ingredient	BOSUTINIB MONOHYDRATE	IMATINIB MESYLATE
Manufacturer	Pf Prism Cv	Shorla Oncology
Dosage forms	Capsule, Tablet	Solution
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Bcr-Abl Positive Chronic Myelogenous Leukemia	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

bosulif imkeldi

Rating

New

Pharmacy pays

—

~$25.80 /30

Type

Active ingredient

BOSUTINIB MONOHYDRATE

IMATINIB MESYLATE

Manufacturer

Pf Prism Cv

Shorla Oncology

Dosage forms

Capsule, Tablet

Solution

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Bcr-Abl Positive Chronic Myelogenous Leukemia

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

What is the difference between Bosulif and Imkeldi?

Bosulif contains Bosutinib Monohydrate, while Imkeldi contains Imatinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.